Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

Egle CorradoGiuseppe DattiloGiuseppe CoppolaClaudia MorabitoEnrico BonniLuca ZappiaGiuseppina NovoCesare de Gregorio

Published in: European journal of clinical pharmacology (2021)

One-year ARNI treatment was effective in our real-life HFrEF patient population, leading to clinical and functional improvement in both study groups, slightly greater and with a shorter time to benefit in group B.

Keyphrases

high dose
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
low dose
peritoneal dialysis
prognostic factors
case report
physical activity